Wilson’s disease: how to delivery timely diagnosis and treatment?


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Wilson's disease belongs to the group of hereditary diseases for which pathogenetic therapy has been developed, which allows, with timely initiation of treatment, to avoid the severe consequences of excessive accumulation of copper in the body. However, due to the rarity of pathology, the variety of clinical manifestations and the low alertness of doctors, the diagnosis is established at the stage of irreversible changes, which significantly worsens the prognosis of patients. All this determines the relevance of summarizing and discussing current data on epidemiology, features of clinical manifestations, diagnosis and treatment of Wilson's disease.

Full Text

Restricted Access

About the authors

Elena Yu. Eremina

N.P. Ogarev National Research Mordovia State University

Email: eeu61@mail.ru
Dr. med. habil., professor, head of the Department of propaedeutics of internal diseases 430005, Saransk, 68 Bol'shevistskaya Str

Olga A. Strokova

N.P. Ogarev National Research Mordovia State University

Email: strokovaoa@rambler.ru
associate professor, associate professor of the Department of propaedeutics of internal diseases 430005, Saransk, 68 Bol'shevistskaya Str

Marina I. Lityushkina

N.P. Ogarev National Research Mordovia State University

Email: litjushkina@rambler.ru
PhD in Medicine, associate professor, associate professor of the Department of propaedeutics of internal diseases 430005, Saransk, 68 Bol'shevistskaya Str

References

  1. Клинические рекомендации. Нарушения обмена меди (болезнь Вильсона). Ассоциация медицинских генетиков, Союз педиатров России, некоммерческое партнерство «Национальное общество по изучению болезни Паркинсона и расстройств движений», Российское трансплантологическое общество, автономная некоммерческая организация «Общество детских гастроэнтерологов, гепатологов и нутрициологов», Национальная ассоциация детских реабилитологов. Рубрикатор клинических рекомендаций Минздрава России. ID: 376. 2021. Доступ: https://cr.minzdrav.gov.ru/schema/376_2 (дата обращения - 01.09.2022).
  2. Liu J., Luan J., Zhou X. et al. Epidemiology, diagnosis, and treatment of Wilson's disease.Intractable Rare Dis Res. 2017; 6(4): 249-55. https://dx.doi.org/10.5582/irdr.2017.01057.
  3. Hahn S.H. Population screening for Wilson's disease. Ann N Y Acad Sci. 2014; 1315: 64-69. https://dx.doi.org/10.1111/nyas.12423.
  4. Циммерман Я.С. Болезнь Вильсона - гепатоцеребральная дистрофия. Клиническая медицина. 2017; 95(4): 310-315. http://doi.org/10.18821/0023-2149-2017-95-4-310-315. EDN: YPIAXJ.
  5. Chang I.J., Hahn S.H. The genetics of Wilson disease. Handb Clin Neurol. 2017; 142: 19-34. http://doi.org/10.1016/B978-0-444-63625-6.00003-3.
  6. Bachmann H., Lossner J., Kuhn H.J. et al. Occurrence, genetics and epidemiology of Wilson's disease in East Germany. Proc. 5th.Intern. Symposium on Wilson's disease. In book: Czlonkowska A., van der Hamer C.J.A., editors. Technical Univ Delft. 1991; 121-28.
  7. Wijayasiri P., Hayre J., Nicholson E.S. et al. Estimating the clinical prevalence of Wilson's disease in the UK. JHEP Rep. 2021; 3(5): 100329. https://dx.doi.org/10.1016/j.jhepr.2021.100329.
  8. Баязутдинова Г.М., Щагина О.А., Карунас А.С. с соавт. Спектр мутаций в гене ATP7B у российских больных с болезнью Вильсона-Коновалова. Генетика. 2019; 55(12): 1433-1441. https://dx.doi.org/10.1134/S0016675819120026. EDN: PHEVUE.
  9. Ferenci P. Regional distribution of mutations in the ATP7B gene in patients with Wilson disease impact on genetic testing. Hum Genet. 2006; 120(2): 151-59. https://dx.doi.org/10.1007/s00439-006-0202-5.
  10. Wilson's disease: An update on the diagnostic workup and management. J Clin Med. 2021; 10(21): 5097. https://dx.doi.org/10.3390/jcm10215097.
  11. Ferenci P., Czlonkowska A., Merle U. et al. Late onset Wilson's disease. Gastroenterology. 2007; 132(4): 1294-98. https://dx.doi.org/10.1053/j.gastro.2007.02.057
  12. Wilson D.C., Phillips M.J., Cox D.W. et al. Severe hepatic Wilson's disease in preschool-aged children. J Pediatr. 2000; 137(5): 719-22. https://dx.doi.org/10.1067/mpd.2000.108569.
  13. Ala A., Borjigin J., Rochwarger A. et al. Wilson's disease in septuagenarian siblings: Raising the bar for diagnosis. Hepatology. 2005; 41(3): 668-70. https://dx.doi.org/10.1002/hep.20601.
  14. Czlonkowska A., Rodo M., Gromadzka G. Late onset Wilson's disease: Therapeutic implications. Mov Disord. 2008; 23(6): 896-98. https://dx.doi.org/10.1002/mds.21985.
  15. Cox D.W., Prat L., Walshe J.M. et al. Twenty-four novel mutations in Wilson's disease patients of predominantly European ancestry. Hum Mutat. 2005; 26(3): 280. https://dx.doi.org/10.1002/humu.9358.
  16. Poujois A., Woimant F. Wilson's disease: A 2017 update. Clin Res Hepatol Gastroenterol. 2018; 42(6): 512-20. https://dx.doi.org/10.1016/j.clinre.2018.03.007.
  17. Xiao H., Deng S., Deng X. et al. Mutation analysis of the ATP7B gene in seven Chinese families with Wilson's disease. Digestion. 2019; 99(4): 319-26. https://dx.doi.org/10.1159/000493314.
  18. Thomas G.R., Forbes J.R., Roberts E.A. et al. The Wilson's disease gene: spectrum of mutations and their consequences. Nat Genet. 1995; 9(2): 210-17. https://dx.doi.org/10.1038/ng0295-210.
  19. Loudianos G., Dessi V., Lovicu M. et al. Molecular characterization of Wilson's disease in the Sardinian population - evidence of a founder effect. Hum Mutat. 1999; 14(4): 294-303. https://dx.doi.org/10.1002/(SICI)1098-1004(199910)14:4<294::AID-HUMU4>3.0.C0;2-9.
  20. Gialluisi A., Incollu S., Pippucci Т. et al. The homozygosity index (HI) approach reveals high allele frequency for Wilson's disease in the Sardinian population. Eur J Hum Genet. 2013; 21(11): 1308-11. https://dx.doi.org/10.1038/ejhg.2013.43.
  21. Lutsenko S., Petris M.J. Function and regulation of the mammalian copper-transporting ATPases: Insights from biochemical and cell biological approaches. J Membr Biol. 2003; 191(1): 1-12. https://dx.doi.org/10.1007/s00232-002-1040-6.
  22. European Association for Study of Liver. EASL clinical practice guidelines: Wilson's disease. J Hepatol. 2012; 56(3): 671-85. https://dx.doi.org/10.1016/j.jhep.2011.11.007.
  23. Cztonkowska A., Tarnacka B., Litwin T. et al. Wilson's disease-cause of mortality in 164 patients during 1992-2003 observation period. J Neurol. 2005; 252(6): 698-703. https://dx.doi.org/10.1007/s00415-005-0720-4.
  24. Palumbo C.S., Schilsky M.L. Clinical practice guidelines in Wilson's disease. Ann Transl Med. 2019; 7(Suppl 2): S65. https://dx.doi.org/10.21037/atm.2018.12.53
  25. Hedera P. Update on the clinical management of Wilson's disease. Appl Clin Genet. 2017; 10: 9-19. https://dx.doi.org/10.2147/TACG.S79121.
  26. Eisenbach C., Sieg O., Stremmel W. et al. Diagnostic criteria for acute liver failure due to Wilson's disease. World J Gastroenterol. 2007; 13(11): 1711-14. https://dx.doi.org/10.3748/wjg.v13.i11.1711.
  27. Litwin T., Dziezyc K., Karlinski M. et al. Early neurological worsening in patients with Wilson's disease. J Neurol Sci. 2015; 355(1-2): 162-67. https://dx.doi.org/10.1016/j.jns.2015.06.010.
  28. Zare E., Mahbubi Z., Panahi M. A neglected case of Wilson's disease presenting as symptomatic urolithiasis and proteinuria: A case report and review of the literature. Journal of Renal and Hepatic Disorders. 2021; 5(2): 39-44. https://dx.doi.org/10.15586/jrenhep.v5i2.123.
  29. Ye X.N., Mao L.P., Lou Y.J. et al. Hemolytic anemia as first presentation of Wilson's disease with uncommon ATP7B mutation.Int J Clin Exp Med. 2015; 8(3): 4708-11.
  30. Grandis D.J., Nah G., Whitman I.R. et al. Wilson's disease and cardiac myopathy. Am J Cardiol. 2017; 120(11): 2056-60. https://dx.doi.org/10.1016/j.amjcard.2017.08.025.
  31. Tarnacka B., Rodo M., Cichy S. et al. Procreation ability in Wilson's disease. Acta Neurol Scand. 2000; 101(6): 395-98. https://dx.doi.org/10.1034/j.1600-0404.2000.90140a.x.
  32. Баязутдинова Г.М., Щагина О.А., Поляков А.В. Мутация c3207C>A гена АТР7В - наиболее частая причина гепатолентикулярной дегенерации в России: частота и причина распространения. Медицинская генетика. 2018; 17(4): 25-30. https://dx.doi.org/10.25557/2073-7998.2018.04.25-30. EDN: OTEJAD.
  33. Nagral A., Sarma M.S., Matthai J. et al. Wilson's disease: Clinical practice guidelines of the Indian National Association for Study of the Liver, the Indian Society of Pediatric Gastroenterology, Hepatology and Nutrition, and the Movement Disorders Society of India. J Clin Exp Hepatol. 2019; 9(1): 74-98. https://dx.doi.org/10.1016/j.jceh.2018.08.009.
  34. Appenzeller-Herzog C., Mathes T., Heeres M.L.S. et al.Comparative effectiveness of common therapies for Wilson's disease: A systematic review and meta-analysis of controlled studies. Liver Int. 2019; 39(11): 2136-52. https://dx.doi.org/10.1111/liv.14179.
  35. Alvarez H.M., Xue Y., Robinson C.D. et al. Tetrathiomolybdate inhibits copper trafficking proteins through metal cluster formation. Science. 2010. 327(5963): 331-34. https://dx.doi.org/10.1126/science.1179907.
  36. Weiss K.H., Askari F.K., Czlonkowska A. et al. Bischoline tetrathiomolybdate in patients with Wilson's disease: An open-label, multicentre, phase 2 study. Lancet Gastroenterol Hepatol. 2017; 2(12): 869-76. https://dx.doi.org/10.1016/S2468-1253(17)30293-5.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies